The purpose of this study was to determine the incidence of and pharmacokinetic parameters associated with the development of transient encephalopathy following the administration of high-dose methotrexate and intrathecal chemotherapy in children with acute lymphoblastic leukemia (ALL). Two hundred and fifty-nine children with newly diagnosed ALL treated on one of two consecutive trials were analyzed. Presenting features in patients who developed transient encephalopathy were compared with those of patients who did not experience this event. For each patient who developed transient encephalopathy, methotrexate pharmacokinetic parameters were compared with those of matched controls. The cumulative incidence of acute encephalopathy was 3% (SE 1%) at 1 year and was associated with age greater than or equal to 10 years at diagnosis. Pharmacokinetic data did not differ between patients who developed transient encephalopathy and those who did not. The majority of patients had no long-term sequelae and were able to receive further courses of methotrexate without modification. Transient focal neurologic deficits occur in about 3% of children with ALL following the administration of intravenous and intrathecal methotrexate. These events cannot be predicted by pharmacokinetic parameters of methotrexate disposition. However, these events are generally benign, suggesting that patients who experience acute encephalopathy should continue to receive this important chemotherapeutic agent.
Introduction
Methotrexate (MTX) is an essential component of therapy for acute lymphoblastic leukemia (ALL) and osteosarcoma. [1] [2] [3] [4] [5] In the treatment of ALL, MTX is given orally or parenterally in doses ranging from 20 mg/m 2 to 8 g/m 2 and is also given intrathecally. However, the optimum dose, schedule, and cumulative dose remains unknown. 5 For osteosarcoma, even higher doses of MTX (8-12 g/m 2 ) are used. Toxicities associated with MTX administration include mucositis, myelosuppression, renal dysfunction, and neurotoxicity. [5] [6] [7] Neurotoxicity, which has been observed after intrathecal, low-dose, and high-dose MTX (HD-MTX), can occur both chronically and acutely. Chronic MTX-induced leukoencephalopathy, a commonly described but poorly understood phenomenon, may severely impair neuropsychologic function, is associated with the use of HD-MTX or inadequate leucovorin rescue, and may be exacerbated by prior cranial irradiation. [7] [8] [9] [10] [11] By contrast, MTX can also cause acute or subacute neurotoxicity that is characterized by confusion, disorientation, seizures, and focal neurologic deficits. [12] [13] [14] [15] [16] Whereas chronic MTX-induced leukoencephalopathy is progressive and dose-limiting, acute While acute encephalopathy has been well-described in osteosarcoma patients, occurring in up to 15% of cases, 13 relatively little is known about this complication in children with ALL. Moreover, there are few data on continued treatment with HD-MTX in patients who developed encephalopathy. From a total population of 259 patients, we now report eight patients who developed acute transient encephalopathy with hemiparesis following the administration of 2 g/m 2 of intravenous MTX for the treatment of ALL.
Materials and methods

Patients
From December 1991 to April 1996, 259 children with newly diagnosed ALL were enrolled on St Jude Children's Research Hospital Total Therapy studies XIIIA and B, which included 10 courses of HD-MTX given at a dose of 2 g/m 2 intravenously over 2 h (500 mg/m 2 intravenous push followed by 1500 mg/m 2 intravenously over 2 h in 100 ml of 5% dextrose). 17 Patients received hydration with 5% dextrose and 40 mEq/l NaHCO 3 in 0.25% normal saline at 200 ml/m 2 /h for at least 8 h. Leucovorin was given at a dose of 10 mg/m 2 every 6 h for five doses beginning 44 h after the start of the HD-MTX infusion. Leucovorin doses were increased in patients with serum MTX levels greater than 0.8 m at 44 h and continued until concentrations were less than 0.1 m. Intrathecal methotrexate, hydrocortisone, and cytarabine (ITMHA) were given in an age-adjusted dose on the morning of HD-MTX administration (generally 6-7 h prior to HD-MTX; see Table  1 ). Approximately one-third of the patients also received one course of 1 g/m 2 MTX given over 24 h prior to starting remission induction therapy. No patients received cranial irradiation prior to the last dose of HD-MTX. Written informed consent was obtained from patients or their legal guardians, and all studies were approved by our Institutional Review Board.
Pharmacokinetic analysis
Plasma concentrations of MTX were measured prior to and at 3, 7, 23 and 44 h from the start of the MTX infusion, using a fluorescence polarization immunoassay (TDx, Abbot Laboratories, Chicago, IL, USA). Pharmacokinetic parameters (Vc, Ke, Kcp and Kpc) were estimated using a MAP Bayesian estimation algorithm as implemented in Adapt II software, with mean (CV%) prior parameter estimates of 20.6 l/m 2 (38%), 0.435 h −1 (19%), 0.0205 h −1 (57%) and 0.0855 h −1 (30%). 6 Clearance was estimated as Vc × Ke, and AUC (area under the plasma concentration vs time curve) was estimated as dose divided by clearance.
Statistical methods
Fisher's exact tests were used to determine whether or not patient age at diagnosis, sex, presenting leukocyte count, central nervous system (CNS) status, immunophenotype, or risk group (as defined by protocol) differed in their distributions between ALL patients who developed transient encephalopathy and those who did not. The number of patients used in each Fisher's exact test was subject to change, as information regarding each presenting feature of interest was not available for each patient.
For purposes of comparison of pharmacokinetic parameters, each patient who developed neurotoxicity was matched to two or three controls who did not. Controls had no seizure or neurological disorders and were taking no chronic psychoactive medications. Patients were matched on the basis of treatment protocol (Total XIIIA or XIIIB) and pre-induction MTX therapy (none, 1 g/m 2 intravenously over 24 h, or 30 mg/m 2 orally every 6 h for six doses). Patients were also matched on the basis of age at diagnosis (±1.5 years), because age was found to be significantly associated with the presence or absence of transient encephalopathy.
The following pharmacokinetic measures were analyzed for association with the development of transient encephalopathy: the sum, maximum, and average MTX AUC, the sum of the leucovorin dose × leucovorin rescue duration, the sum and maximum plasma concentration of MTX before the administration of HD-MTX, and the sum and minimum time between administration of ITMHA and start of the intravenous MTX. An exact stratified logistic regression analysis was performed to test for an association between each summary measure and the presence or absence of transient encephalopathy, where the strata were defined by each case and his or her respective controls. Comparisons between cases and controls were made using all course data available for each patient, as well as using data truncated within each strata according to the number of HD-MTX courses each case received prior to the development of transient encephalopathy.
The methods of Kalbfleisch and Prentice 18 were used to estimate the cumulative incidence of transient encephalopathy, controlling for relapse and death as competing risks.
All statistical analyses were considered significant at a type I error rate of ␣ = 0.05. All P values reported are two-sided and have not been adjusted for multiple testing. All analyses were conducted using SAS Release 6.12 and LogXact version 2.0.
Results
Among 259 patients who received approximately 1650 courses of HD-MTX, eight patients experienced symptoms of acute and transient encephalopathy, resulting in a cumulative incidence (±1 s.e.) of 3 ± 1% at one year ( Figure 1 ). All eight patients presented with signs of focal neurologic deficits, including hemiparesis, beginning 5-13 days after administration of HD-MTX with ITMHA and resolving in 1-3 days (Table 1) . Symptoms generally occurred early in therapy, after one to five courses of HD-MTX, except in patient 5, who experienced encephalopathy after his ninth course of HD-MTX. In all cases, neurologic symptoms resolved spontaneously, and the majority of patients received further courses of HD-MTX without difficulty and without modification of administration (Table 1 ). All eight patients received further courses of low-dose MTX (40 mg/m 2 ) and most received additional ITMHA. Exceptions include patient 1, who had a hematologic relapse prior to receiving his sixth course of HD-MTX, patient 3, who received no intrathecal MTX at (Table 1) . CT and MRI scans of the brain were both normal after this course of HD-MTX. Following his second course of HD-MTX, however, this patient experienced hemiparesis. His CT scan remained normal, but a head MRI showed white matter changes consistent with necrotizing leukoencephalopathy. By contrast, all other patients in this study had normal head MRI scans. Patient 8 received no further HD-MTX or intrathecal MTX, with subsequent intrathecal injections consisting of cytarabine and hydrocortisone. This patient developed a CNS relapse at 9 months.
Clinical features of all patients who experienced transient encephalopathy are shown in Table 1 . Among the presenting features analyzed, only age greater than or equal to 10 years at diagnosis was significantly associated with the development of acute encephalopathy (seven of 78 patients Ͻ1 or Ն10 years old vs one of 181 patients 1-10 years old; P = 0.001). There were no significant differences in the distributions of other presenting features, including sex, leukocyte count, CNS status, immunophenotype, and ALL risk group between the patients who developed transient encephalopathy and those who did not.
Results of the exact stratified logistic regression analyses using all course data available for each patient indicate that there is no association between any of the pharmacokinetic summary measures of interest and the presence or absence of transient encephalopathy (Table 2) . Similarly, results of the exact stratified logistic regression analyses using data truncated within each strata according to the number of MTX courses each case received prior to his or her neurotoxic episode indicate that there is no association between any of the pharmacokinetic summary measures of interest and the presence or absence of transient encephalopathy (Table 3) . Summary statistics for other various pharmacokinetic parameters were also calculated for the cases and controls (Table 4d) .
Discussion
An acute encephalopathy that is characterized by transient focal neurologic deficits beginning within 2 weeks of MTX administration (at high or low doses, with or without intrathecal therapy) has been reported in both osteosarcoma and ALL patients. [12] [13] [14] [15] Most patients recover fully, although some suffer recurrences during subsequent courses of MTX. Evaluation usually reveals normal head CT or MRI scans, normal cerebrospinal fluid, and generalized slowing on EEG. 13 Although transient cerebral dysfunction following the administration of 8-12.5 g/m 2 of MTX has been observed in up to 15% of patients being treated for osteosarcoma, 12,13 more recent trials have not reported this event. [19] [20] [21] [22] HD-MTX is generally given at a dose of 1-5 g/m 2 for the treatment of childhood ALL; transient encephalopathy has only rarely been reported after these doses. Kubo et al 23 reported a 4-year-old girl with ALL who developed seizures and hemiparesis 5 days after receiving a single course of 1 g/m 2 MTX. Savage et al 24 described two ALL patients who developed hemiparesis and expressive dysphagia 6-13 days following a third course of 1.8 g/m 2 MTX. Two children with ALL developed transient leukoencephalopathy following the administration of intravenous cytarabine (1 g/m 2 ) and MTX (0.5 g/m 2 ). 25 Similarly, transient hemiparesis and permanent leukoencephalopathy have both been reported following the administration of intravenous cytarabine and methotrexate at 1 g/m 2 each. 26 More recently, the Pediatric Oncology Group reported neurotoxicity, primarily seizures, in 8% of ALL patients who received 1 g/m 2 of intravenous methotrexate; however, the incidence of transient encephalopathy was not specified. 5 Transient neurologic deficits have also been reported in ALL patients receiving intrathecal and low-dose oral methotrexate. 16 In a study of 138 ALL patients, 25 experienced acute neurotoxicity approximately 10 days following the simultaneous administration of intrathecal methotrexate (with or without cytarabine) and intravenous cytarabine and etoposide. 16 Although the majority of these events were seizures, six patients had transient neurologic deficits characterized by hemiparesis that resolved within 24 h. Acute neurotoxicity was eliminated by the addition of leucovorin rescue to the treatment regimen. Thus, the incidence of encephalopathy that we observed with HD-MTX plus ITMHA is similar to the incidence reported with low-dose MTX plus intrathecal therapy. 16 In the present analysis, eight of 259 patients developed acute and transient neurologic changes following the administration of 2 g/m 2 intravenous MTX given simultaneously with ITMHA. Similar to the transient cerebral dysfunction seen following HD-MTX alone in osteosarcoma patients, 12,13 all events reported herein occurred within 13 days of a HD-MTX infusion and all resolved within 3 days of onset. Moreover, like osteosarcoma patients, seven of the eight patients presented in this report had normal imaging studies and were able to receive additional HD-MTX courses without complications. Although follow-up time is short, none of these seven patients has demonstrated manifestations of long-term toxicity. Only one patient had subsequent radiologic evidence of leukoencephalopathy and received no further HD-MTX.
Our results indicate that patients greater than or equal to 10 years of age are at a higher risk of developing transient encephalopathy than patients aged 1-10 years old. In contrast, Winick et al 16 found no difference in the ages of patients who did and did not develop neurotoxicity. We hypothesized that the tendency for lower MTX clearance in adolescents might contribute to this association with age. However, MTX pharmacokinetic parameters were not different in those patients who did and did not develop encephalopathy. This lack of association between MTX disposition and neurotoxicity was also reported following low-dose MTX. 16 Thus, the mechanism underlying the increased risk of encephalopathy in patients greater than 10 years old is not clear.
Although acute MTX-induced neurotoxicity was first described over 20 years ago, its mechanism remains largely unknown. 27 The acute onset and reversibility have suggested a vascular etiology, such as intracranial vasculitis, emboli, or vascular occlusion, 12 possibly exacerbated or initiated by metabolic disturbances. 13, 16, 27 For example, it has been proposed that neurotoxicity may result from altered neurotransmitter levels secondary to inhibition of tetrahydrobiopterin synthesis, 13, 28 or from increased adenosine 29 or homocysteine 16 levels. Homocysteine, which is increased in patients treated with MTX, causes direct vascular endothelium injury and may, therefore, result in ischemia-mediated neurotoxicity. 30, 31 In addition, homocysteine is metabolized to excitatory amino acid neurotransmitters, which may be higher in the cerebrospinal fluid of patients who have received MTX. 32 In summary, we found that the 1-year cumulative incidence of acute encephalopathy in children with ALL was 3 ± 1% and that acute encephalopathy occurred more frequently in older children, but was not related to MTX pharmacokinetics, and generally had a benign course. In most cases, these patients are able to tolerate further courses of HD-MTX and ITMHA and should, therefore, continue to receive these important components of therapy.
